FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in TreatmentPublished: February 20, 2025On January 27,…
FDA Approves Mirdametinib for NF1-PN: A New Option for PatientsIntroduction: The FDA has recently approved Mirdametinib (Gomekli) from SpringWorks Therapeutics…
